1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Merck & Co’s TROP2 Partner Trumpets Phase III Success In TNBC

Kelun Planning China Filings

 
• By Kevin Grogan

Merck & Co's antibody-drug conjugates pact with Kelun is progressing well and the lead candidate of the pact, the TROP2-targeting candidate codenamed SKB264/MK-2870, has significantly improved progression-free survival in triple-negative breast cancer patients in a late-stage trial in China.

• Source: Shutterstock

Merck & Co., Inc.'s advances into the antibody-drug conjugate space through its partnership with Sichuan Kelun Pharmaceutical Co Ltd. continue to bear fruit with the Chinese biotech heralding success in a late-stage study for the leading compound in the pact, MK-2870/SKB264, in the treatment of triple-negative breast cancer (TNBC).

Kelun has announced that an independent data monitoring committee has concluded an interim analysis of data from a Phase III...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.